908 Devices Inc. | Micro-cap | Healthcare
$6.41
-3.61%
| 908 Devices Stock Comparison:
908 Devices vs Abbott Laboratories908 Devices vs Boston Scientific908 Devices vs MaxCyte908 Devices vs Tactile Systems908 Devices vs Perspective908 Devices vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 59.6M
Gross Profit 29.9M 50.07%
Operating Income -49.3M -82.63%
Net Income -72.2M -121.09%
EPS (Diluted) -$2.12

Balance Sheet Metrics

Total Assets 159.5M
Total Liabilities 44.9M
Shareholders Equity 114.6M
Debt to Equity 0.39

Cash Flow Metrics

Operating Cash Flow -73.7M
Free Cash Flow -30.8M

Revenue & Profitability Trend

908 Devices Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue59.6M50.2M46.9M42.2M26.9M
Cost of Goods Sold29.8M24.9M20.8M19.0M12.0M
Gross Profit29.9M25.3M26.0M23.2M14.9M
Operating Expenses79.1M68.1M61.4M45.3M20.7M
Operating Income-49.3M-42.8M-35.4M-22.1M-5.8M
Pre-tax Income-72.5M-36.6M-33.6M-22.2M-12.8M
Income Tax-282.0K-211.0K0--
Net Income-72.2M-36.4M-33.6M-22.2M-12.8M
EPS (Diluted)-$2.12-$1.13-$1.07-$0.79-$2.35

Income Statement Trend

908 Devices Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets103.1M173.8M215.6M252.9M171.0M
Non-Current Assets56.4M29.2M27.0M8.0M7.9M
Total Assets159.5M203.0M242.6M260.9M178.8M
Liabilities
Current Liabilities25.1M22.5M19.2M14.8M10.8M
Non-Current Liabilities19.7M14.9M32.8M31.5M29.0M
Total Liabilities44.9M37.5M52.0M46.3M39.8M
Equity
Total Shareholders Equity114.6M165.5M190.6M214.6M139.0M

Balance Sheet Composition

908 Devices Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-72.2M-36.4M-33.6M-22.2M-12.8M
Operating Cash Flow-73.7M-27.3M-22.6M-29.6M-4.2M
Investing Activities
Capital Expenditures-602.0K-2.0M-2.0M-737.0K-9.0K
Investing Cash Flow-46.3M-26.4M-15.8M-737.0K-9.0K
Financing Activities
Dividends Paid-----
Financing Cash Flow-376.0K-15.9M1.2M109.7M137.1M
Free Cash Flow-30.8M-27.1M-23.0M-29.8M4.1M

Cash Flow Trend

908 Devices Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3.12
Forward P/E -6.21
Price to Book 1.49
Price to Sales 3.72
PEG Ratio -6.21

Profitability Ratios

Profit Margin -27.64%
Operating Margin -72.40%
Return on Equity -48.15%
Return on Assets -16.03%

Financial Health

Current Ratio 7.62
Debt to Equity 2.36
Beta 0.28

Per Share Data

EPS (TTM) -$2.22
Book Value per Share $4.46
Revenue per Share $1.84

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mass238.1M-3.121.49-48.15%-27.64%2.36
Abbott Laboratories 231.9B17.314.7530.65%31.89%27.09
Boston Scientific 149.9B73.946.759.50%11.58%52.16
MaxCyte 230.7M-5.681.16-19.63%-110.92%9.44
Tactile Systems 236.4M15.411.178.12%5.52%21.23
Perspective 256.8M-3.340.90-32.92%0.00%1.34

Financial data is updated regularly. All figures are in the company's reporting currency.